Literature DB >> 7599172

Attachment of articular cartilage chondrocytes to the tissue form of type VI collagen.

J Marcelino1, C A McDevitt.   

Abstract

Type VI collagen is composed of a short triple helix rich in RGD sequences with globular domains at each extremity of the helix. Disulfide-bonded tetramers of the monomeric molecule associate non-covalently to form networks of microfibrils in connective tissues, including cartilage. The disulfide-bonded tetramer can be extracted with 6 M guanidine HCl and purified without pepsin digestion and is referred to here as the tissue form of type VI collagen. Type VI collagen in mature articular cartilage appears to be concentrated pericellularly. We undertook a systematic investigation using solid phase assays to establish the nature of the attachment of bovine articular cartilage chondrocytes to the intact, tissue form of bovine type VI collagen. The tissue form of type VI collagen was extracted from bovine meniscus cartilage with 6 M guanidine HCl and purified by polyethylene glycol precipitation. When equal molar quantities were coated on microwells, the tissue form of type VI collagen attached more cells than the pepsin-digested form of the molecule that lacked the globular domains. The attachment to the intact, tissue form was dose-dependent and saturable and was not inhibited by heparin or type II collagen. A linear GRGDSP peptide failed to inhibit attachment of the chondrocytes to the intact, tissue or pepsin-digested forms of type VI collagen, but totally inhibited the interaction when the intact molecule was reduced and alkylated. In contrast, a cyclic C*GRGDSPC* peptide inhibited attachment to the tissue form of type VI collagen, but not to fibronectin. The attachment had a metal ion dependence that could be satisfied by MnCl2, slightly less by MgCl2, but not at all by CaCl2. A direct interaction between the tissue form of type VI collagen and a chondrocyte cell surface receptor or receptors is a structural feature of the pericellular matrix in cartilage.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7599172     DOI: 10.1016/0167-4838(95)00026-q

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  14 in total

1.  Regional variations in the distribution and colocalization of extracellular matrix proteins in the juvenile bovine meniscus.

Authors:  Eric J Vanderploeg; Christopher G Wilson; Stacy M Imler; Carrie Hang-Yin Ling; Marc E Levenston
Journal:  J Anat       Date:  2012-06-18       Impact factor: 2.610

2.  The distribution of type VI collagen in the developing tissues of the bovine femoral head.

Authors:  A F Sherwin; D H Carter; C A Poole; J A Hoyland; S Ayad
Journal:  Histochem J       Date:  1999-09

3.  Type VI Collagen Regulates Pericellular Matrix Properties, Chondrocyte Swelling, and Mechanotransduction in Mouse Articular Cartilage.

Authors:  Nicole A Zelenski; Holly A Leddy; Johannah Sanchez-Adams; Jinzi Zhang; Paolo Bonaldo; Wolfgang Liedtke; Farshid Guilak
Journal:  Arthritis Rheumatol       Date:  2015-05       Impact factor: 10.995

4.  Type II and VI collagen in nasal and articular cartilage and the effect of IL-1alpha on the distribution of these collagens.

Authors:  I D C Jansen; A P Hollander; D J Buttle; V Everts
Journal:  J Mol Histol       Date:  2010-03-06       Impact factor: 2.611

5.  Developmental and osteoarthritic changes in Col6a1-knockout mice: biomechanics of type VI collagen in the cartilage pericellular matrix.

Authors:  Leonidas G Alexopoulos; Inchan Youn; Paolo Bonaldo; Farshid Guilak
Journal:  Arthritis Rheum       Date:  2009-03

6.  Altered trabecular bone structure and delayed cartilage degeneration in the knees of collagen VI null mice.

Authors:  Susan E Christensen; Jeffrey M Coles; Nicole A Zelenski; Bridgette D Furman; Holly A Leddy; Stefan Zauscher; Paolo Bonaldo; Farshid Guilak
Journal:  PLoS One       Date:  2012-03-20       Impact factor: 3.240

7.  Strategies for blocking the fibrogenic actions of connective tissue growth factor (CCN2): From pharmacological inhibition in vitro to targeted siRNA therapy in vivo.

Authors:  David R Brigstock
Journal:  J Cell Commun Signal       Date:  2009-03-18       Impact factor: 5.782

Review 8.  Targeted Therapies in Liver Fibrosis: Combining the Best Parts of Platelet-Derived Growth Factor BB and Interferon Gamma.

Authors:  Fransien van Dijk; Peter Olinga; Klaas Poelstra; Leonie Beljaars
Journal:  Front Med (Lausanne)       Date:  2015-10-05

9.  Targeting activated hepatic stellate cells (aHSCs) for liver fibrosis imaging.

Authors:  Dan Li; Li He; Huizhuang Guo; Hanwei Chen; Hong Shan
Journal:  EJNMMI Res       Date:  2015-12-09       Impact factor: 3.138

Review 10.  Pharmacological Intervention in Hepatic Stellate Cell Activation and Hepatic Fibrosis.

Authors:  Hans-Theo Schon; Matthias Bartneck; Erawan Borkham-Kamphorst; Jacob Nattermann; Twan Lammers; Frank Tacke; Ralf Weiskirchen
Journal:  Front Pharmacol       Date:  2016-02-24       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.